New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT05029141 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Phase 2

Started

2021-09-01

Last updated

2026-03-19

Condition(s) studied

Acute Myeloid LeukemiaRefractory Acute LeukemiaRelapsed Adult AML

Investigational drug(s) / intervention(s)

CAHAG regimenPlacebo regimen

CAHAG regimen: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused). One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.

Placebo regimen: Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused). One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.

Study summary

This study is to investigate the therapeutic efficacy and side effect of chidamide, azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid leukemia

Eligibility

Sex

ALL

Min age

18 Years

Max age

69 Years

Healthy volunteers

Inclusion Criteria: * Adults aged ≥ 18 and ≤ 70 years * Patients diagnosed with AML according to 2016 WHO myeloid malignant disease diagnosis standard (Non-APL) * Patients with AML must meet one of the following criteria, A or B: A: Refractory AML disease was defined as follows: (1) failure to attain CR following exposure to at least 2 courses of standard or intensive induction therapy; or (2) bone marrow leukemia cell decline index (BMCDI) \< 50% and \> 20% after 1 course of standard or intensive induction therapy. B: Relapsed AML disease was defined as follows: (1) reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of ≥ 5% blasts in the BM not attributable to another cause (e.g., BM regeneration after consolidation therapy); or (3) extramedullary relapse. * ECOG performance status score less than 3 * Expected survival time ˃ 3 months * Patients without serious heart, lung, liver, or kidney disease * Ability to understand and voluntarily provide informed consent Exclusion Criteria: * Patients who are allergic to the study drug or drugs with similar chemical structures * Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception * Active infection * Active bleeding * Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment * Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met * Liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, ALT/AST \> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value) * Patients with a history of clinically significant QTc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment * Surgery on the main organs within the past six weeks * Drug abuse or long-term alcohol abuse that would affect the evaluation results * Patients who have received organ transplants (excepting bone marrow transplantation) * Patients not suitable for the study according to the investigator's assessment

Primary outcome measure(s)

Overall response rate (ORR) — At the end of Cycle 1 (each cycle is 28 days)
The overall response (completed remission without minimal residual disease, completed remission with incomplete blood count recovery, morphologic leukemia-free state and partial remission) rate achieved after one or two courses(28 days) induction therapy by CAHAG regimen.
Complete remission without minimal residual disease (CR with MRD-) — At the end of Cycle 1 (each cycle is 28 days)
If studied pretreatment, CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC
Complete remission with incomplete hematologic recovery (CRi) — At the end of Cycle 1 (each cycle is 28 days)
All CR criteria except for residual neutropenia (,1.0\*10E9/L \[1000/uL\]) or thrombocytopenia (\<100\*10E9/L \[100 000/uL\])
Morphologic leukemia-free state (MLFS) — At the end of Cycle 1 (each cycle is 28 days)
Bone marrow blasts ,5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required
Partial remission (PR) — At the end of Cycle 1 (each cycle is 28 days)
All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.

Trial sites (1)

Facility	City	Region	Status
The First Affliated Hospital of Soochow University	Suzhou	Jiangsu

More The First Affiliated Hospital of Soochow University trials in China

A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML Recruiting

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Starting soon

A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia Starting soon

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Active, not recruiting

Other trials for the same condition

CLL-1 CAR-NK Cells for Relapsed/Refractory AML Recruiting

Twice-per-weekSelinexor, 2 Days Melphalan Starting soon

IFN-α in Relapse Prevention. Starting soon

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations Starting soon

Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05029141 on ClinicalTrials.gov ↗ ← All trials in China